Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: To evaluate urinary activated leucocyte cell adhesion molecule (ALCAM) and CD6 as predictors of LN progression or disease resolution across a 1-year study.
Methods: Serum and urine samples from biopsy proven LN subjects (n = 122) were prospectively collected over the course of a year at 3- or 6-month intervals (weeks 0, 12, 26 and 52) across multiple study sites and assessed for soluble ALCAM and CD6 levels. Urine creatinine from the same urine sample was used to normalize the levels of urinary ALCAM and urinary CD6. Measured levels of serum and urine ALCAM and CD6 were then analysed against disease metrics cross-sectionally and longitudinally.
Results: Cross-sectional analysis at baseline revealed that urinary ALCAM significantly correlated with urine protein creatinine ratio, renal SLEDAI, and the Physician Global Assessment (PGA), and negatively correlated with serum C3 and C4. Receiver operating characteristic curve analysis demonstrated that urinary ALCAM is a predictor of LN with an area under the curve (AUC) of 0.97, compared with urinary CD6 with an AUC of 0.71. Importantly, the change in urinary ALCAM over a 3-month period distinguished between non-responders and responders at week 52.
Conclusion: Urinary ALCAM is reflective of changes in LN and may be predictive of response status.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12048083 | PMC |
| http://dx.doi.org/10.1093/rheumatology/keae559 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TFAP2A orchestrates gene regulatory networks and tubular architecture in kidney outer medullary collecting ducts.
JCI Insight
August 2025
Department of Nephrology and Hypertension, Hannover Medical School (MHH), Hannover, Germany.
Mutations in the transcription factor TFAP2A are linked to congenital anomalies of the kidney and urinary tract in humans. While Tfap2a knockout (KO) in mouse collecting ducts leads to tubular epithelial abnormalities, its precise molecular functions in kidney tubules remain unclear. To investigate Tfap2a-dependent gene regulatory networks in the mouse kidney collecting ducts, we employed conditional knockout (Hoxb7-Cre; Tfap2aflox/flox) models combined with transcriptomics.
View Article and Find Full Text PDFAberrant Lower CD6 Expression on Peripheral B Cells Associated With Liver/Kidney Injury and Autoantibody Production of Systemic Lupus Erythematosus Patients.
Scand J Immunol
April 2025
Department of Dermatology, Second Xiangya Hospital, Central South University, Hunan Key Laboratory of Medical Epigenomics, Changsha, Hunan, China.
Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease characterised by aberrant activation and differentiation of autoreactive T and B cells, as well as the overproduction of autoantibodies. CD6, a cell-surface glycoprotein, regulates lymphocyte activation, differentiation and survival, and is implicated in the pathogenesis of various autoimmune disorders. In SLE, the CD6/activated leukocyte cell adhesion molecule (ALCAM) pathway promotes renal T-cell immune responses.
View Article and Find Full Text PDFUrinary Immune Complexes Reflect Renal Pathology in Lupus Nephritis.
Diagnostics (Basel)
December 2024
Department of Biomedical Engineering, University of Houston, Houston, TX 77204, USA.
Background/objectives: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), involving immune complex deposition in the kidneys. While renal biopsy is the diagnostic gold standard, its invasiveness limits frequent use, driving the need for non-invasive urinary biomarkers to monitor disease progression and response to treatment. This study aimed to identify and validate urinary biomarkers for LN.
View Article and Find Full Text PDFSoluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis.
Rheumatology (Oxford)
May 2025
Department of Medicine, Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA.
Objectives: To evaluate urinary activated leucocyte cell adhesion molecule (ALCAM) and CD6 as predictors of LN progression or disease resolution across a 1-year study.
Methods: Serum and urine samples from biopsy proven LN subjects (n = 122) were prospectively collected over the course of a year at 3- or 6-month intervals (weeks 0, 12, 26 and 52) across multiple study sites and assessed for soluble ALCAM and CD6 levels. Urine creatinine from the same urine sample was used to normalize the levels of urinary ALCAM and urinary CD6.
Urinary biomarkers for active Lupus Nephritis that have survived independent validation across cohorts.
Kidney Int
December 2024
Biomedical Engineering Department, University of Houston, Houston, Texas, USA. Electronic address:
Article Synopsis
- Many biomarkers for lupus nephritis have not been validated across different studies, but identifying urinary biomarkers that can differentiate active lupus nephritis from inactive disease is clinically important.* -
- The review assessed 40 studies involving 3,411 patients and identified 32 candidate urinary biomarkers, with 14 of them validated in multiple papers and showing strong diagnostic potential.* -
- These urinary biomarkers can not only assist in diagnosis and monitoring of active lupus nephritis but also provide insights into the underlying kidney processes, suggesting that advancements in proteomics will enhance our understanding even further.*